CMAJ • December 2, 2008; 179 (12). doi:10.1503/cmaj.070804.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendix
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrmann, N.
Right arrow Articles by Gauthier, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, N., MD
Right arrow Articles by Gauthier, S., MD
Related Collections
Right arrow Dementia
Right arrow Diagnosis and Treatment of Dementia Series

Review

Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease

Nathan Herrmann, MD and Serge Gauthier, MD

From the Department of Psychiatry (Herrmann), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.; and the Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, and the Department of Neurology, McGill University (Gauthier), Montréal, Que.

Correspondence to: Dr. Nathan Herrmann, Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Rm. FG05, 2075 Bayview Ave., Toronto ON M4N 3M5; fax 416 480-6022; n.herrmann{at}utoronto.ca

Abstract

Background: The management of severe Alzheimer disease often presents difficult choices for clinicians and families. The disease is characterized by a need for full-time care and assistance with basic activities of daily living. We outline an evidence-based approach for these choices based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.

Methods: We developed evidence-based guidelines using systematic literature searches, with specific criteria for the selection and quality assessment of articles, and a clear and transparent decision-making process. We selected articles published from January 1996 to December 2005 that dealt with the management of severe Alzheimer disease. Subsequent to the conference, we searched for additional articles published from January 2006 to March 2008 using the same search terms. We graded the strength of the evidence using the criteria of the Canadian Task Force on Preventive Health Care.

Results: We identified 940 articles, of which 838 were selected for further study. Thirty-four articles were judged to be of at least good or fair quality and were used to generate 17 recommendations. Assessment of severe Alzheimer disease should include the measurement of cognitive function and the assessment of behaviour, function, medical status, nutrition, safety and caregiver status. Management could include treatment with a cholinesterase inhibitor or memantine, or both. Treatment of neuropsychiatric symptoms begins with nonpharmacologic approaches to addressing behavioural problems. Severe agitation, aggression and psychosis, which are potentially dangerous to the patient, the caregiver and others in the environment, can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular events and death. All pharmacologic approaches require careful monitoring and periodic reassessment to determine whether continued treatment is necessary. Caregiver support and use of community resources are essential.

Interpretation: Severe Alzheimer disease requires frequent monitoring by health professionals. Simple nonpharmacologic approaches may address problems with mood and agitation. Antipsychotic drug therapy is occasionally necessary despite the inherent risks. Therapy with a cholinesterase inhibitor and memantine may be useful for selected patients.




eLetters:

Read all eLetters

A profoundly flawed recommendation
Henry Schneiderman
CMAJ, 16 Jan 2009 [Full text]
Response to Dr. Schneiderman
Nathan Herrmann
CMAJ, 29 Jan 2009 [Full text]